Impact of clinical and molecular parameters on early response parameters (multivariate analysis)
| Parameter . | Comparison . | P . | OR . | Lower CI . | Upper CI . |
|---|---|---|---|---|---|
| Early blast cell clearance | |||||
| NPM1 | Pos vs neg | < .001 | 3.12 | 2.01 | 4.83 |
| Initial BM blasts, % | +10 | .019 | 0.90 | 0.82 | 0.98 |
| CR | |||||
| NPM1 | Pos vs neg | < .001 | 2.81 | 1.84 | 4.29 |
| WBC, ×109/L | 10-fold | < .001 | 0.53 | 0.39 | 0.72 |
| Age, y | +10 | .006 | 0.81 | 0.69 | 0.94 |
| Parameter . | Comparison . | P . | OR . | Lower CI . | Upper CI . |
|---|---|---|---|---|---|
| Early blast cell clearance | |||||
| NPM1 | Pos vs neg | < .001 | 3.12 | 2.01 | 4.83 |
| Initial BM blasts, % | +10 | .019 | 0.90 | 0.82 | 0.98 |
| CR | |||||
| NPM1 | Pos vs neg | < .001 | 2.81 | 1.84 | 4.29 |
| WBC, ×109/L | 10-fold | < .001 | 0.53 | 0.39 | 0.72 |
| Age, y | +10 | .006 | 0.81 | 0.69 | 0.94 |
The candidate prognostic factors included were mutations of the molecular markers NPM1, FLT3-ITD, FLT3-TKD, MLL-PTD, CEBPA, and the clinical parameters age, sex, ECOG performance status, AML de novo, WBC, platelet count, hemoglobin level, LDH, and amount of BM blasts. The analyses were performed using 514 complete cases with regard to CR rate and 448 complete cases with regard to day-16 blast clearance for the candidate prognostic factors. The multivariate prognostic factors were identified using backward Wald logistic regression model with a significance level of 5%.
OR indicates odds ratio for achieving a CR/early blast cell clearance; lower CI, lower limit of the 95% confidence interval; and upper CI, upper limit of the 95% confidence interval.